Related Experiment Video
Updated: Jun 30, 2026

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes
Published on: June 16, 2011
TRIB3 [corrected] is implicated in glucotoxicity- and endoplasmic reticulum-stress-induced [corrected] beta-cell
Bo Qian1, Haiyan Wang, Xiuli Men
1Graduate School of Peking Union Medical College, Beijing 100730, People's Republic of China.
Abstract:
We found that TRIB3, [corrected] an endogenous inhibitor of Akt (PKB), is expressed in pancreatic beta-cells. The TRIB3 [corrected] expression is significantly increased in islets isolated from hyperglycemic Goto-Kakizaki rats compared with normal glycemic controls. In vitro high glucose treatment also resulted in increased TRIB3 [corrected] expression in rat INS1 cells. To investigate the role of TRIB3 [corrected] in the regulation of beta-cell function, we established an INS1 stable cell line allowing inducible expression of TRIB3. [corrected] We demonstrated that overexpression of TRIB3 [corrected] mimicked the glucotoxic effects on insulin secretion and cell growth in INS1 cells. Moreover, induction of TRIB3 [corrected] also synergistically enhanced high-glucose-elicited apoptosis in INS1 cells, whereas siRNA knock-down of TRIB3 [corrected] showed the opposite effects. We also confirmed that the DeltaPsim of mitochondria was decreased, caspase-3 activity was up-regulated and reactive oxygen species content was increased in TRIB3 [corrected] overexpressing beta cells in high glucose condition. Most interestingly, the oestrogen receptor (ER) stress inducer, thapsigargin, mimicked the high glucose effects on up-regulation of TRIB3 [corrected] and generation of apoptosis in cultured INS1 cells. These effects were specifically prevented by siRNA knock down of TRIB3. [corrected] We therefore conclude that TRIB3 [corrected] is implicated in glucotoxicity- and ER stress-induced beta-cell failure.TRIB3 [corrected] could be a potential pharmacological target for prevention and treatment of type 2 diabetes.
Insights
Trib3 protein inhibits Akt and is elevated in high glucose conditions, contributing to pancreatic beta-cell failure. Targeting Trib3 may offer a new treatment for type 2 diabetes.
Area of Science:
- Endocrinology
- Molecular Biology
- Cell Biology
Background:
- Trib3 (Tribbles homolog 3) is an endogenous inhibitor of Akt (Protein Kinase B).
- Increased Trib3 expression is observed in pancreatic beta-cells under hyperglycemic conditions.
Purpose of the Study:
- To investigate the role of Trib3 in regulating pancreatic beta-cell function and survival.
- To explore Trib3 as a potential therapeutic target for type 2 diabetes.
Main Methods:
- Established an inducible Trib3-expressing INS1 cell line.
- Utilized small interfering RNA (siRNA) to knock down Trib3 expression.
- Assessed insulin secretion, cell growth, apoptosis, mitochondrial membrane potential, caspase-3 activity, and reactive oxygen species.
Main Results:
- Trib3 overexpression mimicked high glucose effects, impairing insulin secretion and cell growth.
- Trib3 induction enhanced high glucose-induced apoptosis; Trib3 knockdown had opposite effects.
- High glucose and ER stress both upregulate Trib3, leading to beta-cell dysfunction and apoptosis.
Conclusions:
- Trib3 is implicated in glucotoxicity and ER stress-induced pancreatic beta-cell failure.
- Trib3 represents a potential pharmacological target for type 2 diabetes prevention and treatment.
Related Concept Videos
Type II Diabetes II: Pathophysiology
Type I Diabetes II: Pathophysiology
Regulation of the Unfolded Protein Response
Acute Pancreatitis II: Pathophysiology
Type II Diabetes I: Introduction
Type I Diabetes III: Clinical Manifestations
